Overdose has not been reported. Based upon the pharmacodynamics of the drug, toxicity is likely to be reflected as anticoagulation, bleeding, thrombocytopenia, liver function abnormalities, and gastric distress. (See CLINICAL PHARMACOLOGY and PRECAUTIONS sections.) At a daily dose of 900 mg for 32 weeks (n = 127) in a clinical trial, rectal hemorrhage was reported as an adverse event in 15% of patients. At a daily dose of ELMIRON (pentosan polysulfate sodium capsules) ® 900 mg for 16 weeks in a clinical trial that enrolled 51 patients in the ELMIRON (pentosan polysulfate sodium capsules) ® group and 49 in the placebo group, elevated liver function tests were reported as an adverse event in 11.8% of patients in the ELMIRON (pentosan polysulfate sodium capsules) ® group and 2% of patients in the placebo group. In the event of acute overdosage, the patient should be given gastric lavage if possible, carefully observed and given symptomatic and supportive treatment.
ELMIRON (pentosan polysulfate sodium capsules) ® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients.
Last reviewed on RxList: 2/4/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Elmiron Information
Elmiron - User Reviews
Elmiron User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
Find out what women really need.